NasdaqCM:AVXL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. More Details


Snowflake Analysis

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Anavex Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AVXL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: AVXL's weekly volatility has increased from 15% to 21% over the past year.


Market Performance


7 Day Return

3.8%

AVXL

-4.9%

US Biotechs

-3.6%

US Market


1 Year Return

241.7%

AVXL

33.8%

US Biotechs

36.4%

US Market

Return vs Industry: AVXL exceeded the US Biotechs industry which returned 34.8% over the past year.

Return vs Market: AVXL exceeded the US Market which returned 38.9% over the past year.


Shareholder returns

AVXLIndustryMarket
7 Day3.8%-4.9%-3.6%
30 Day115.9%-2.1%0.9%
90 Day142.5%6.6%6.7%
1 Year241.7%241.7%35.8%33.8%39.4%36.4%
3 Year400.8%400.8%19.1%13.0%53.4%43.5%
5 Year191.3%191.3%52.1%41.0%117.3%93.0%

Long-Term Price Volatility Vs. Market

How volatile is Anavex Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Anavex Life Sciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AVXL ($13.02) is trading below our estimate of fair value ($49.83)

Significantly Below Fair Value: AVXL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AVXL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AVXL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVXL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVXL is overvalued based on its PB Ratio (18.8x) compared to the US Biotechs industry average (4.3x).


Next Steps

Future Growth

How is Anavex Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

75.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVXL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AVXL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AVXL's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if AVXL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AVXL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AVXL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Anavex Life Sciences performed over the past 5 years?

-16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVXL is currently unprofitable.

Growing Profit Margin: AVXL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVXL is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.

Accelerating Growth: Unable to compare AVXL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-32.1%).


Return on Equity

High ROE: AVXL has a negative Return on Equity (-59.49%), as it is currently unprofitable.


Next Steps

Financial Health

How is Anavex Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: AVXL's short term assets ($54.3M) exceed its short term liabilities ($8.0M).

Long Term Liabilities: AVXL has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AVXL is debt free.

Reducing Debt: AVXL has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVXL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AVXL has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 27.2% each year.


Next Steps

Dividend

What is Anavex Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVXL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVXL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVXL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Chris Missling (54 yo)

7.58yrs

Tenure

US$1,841,048

Compensation

Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and had been its Chief Financial O...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD1.84M) is about average for companies of similar size in the US market ($USD2.22M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Missling
Chairman7.58yrsUS$1.84m1.47%
$ 13.3m
Sandra Boenisch
Principal Financial Officer & Treasurer5.33yrsUS$295.22k0.033%
$ 299.0k
Stephan Toutain
Chief Operating Officer2.92yrsno datano data
Emmanuel Fadiran
Senior Vice President of Regulatory Affairsno datano datano data
Walter Kaufmann
Chief Medical Officerno datano datano data
Clint Tomlinson
Executiveno datano datano data

5.3yrs

Average Tenure

54yo

Average Age

Experienced Management: AVXL's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Missling
Chairman7.58yrsUS$1.84m1.47%
$ 13.3m
Jeffrey Cummings
Member of the Scientific Advisory Board9.92yrsno datano data
Jacqueline French
Member of the Scientific Advisory Board5.92yrsno datano data
Paul Aisen
Member of the Scientific Advisory Board10yrsno datano data
John Harrison
Member of the Scientific Advisory Board7.17yrsno datano data
Ottavio Arancio
Member of the Scientific Advisory Board7.25yrsno datano data
Tangui Maurice
Member of the Scientific Advisory Boardno datano datano data
Elliot Favus
Independent Director6.75yrsUS$111.32kno data
Athanasios Skarpelos
Independent Director8.08yrsUS$111.32k1.88%
$ 17.0m
Norman Relkin
Member of the Scientific Advisory Board6.75yrsno datano data
Corinne Lasmézas
Member of the Scientific Advisory Board5.92yrsno datano data
Claus van der Velden
Independent Director2.92yrsUS$127.32kno data

7.2yrs

Average Tenure

53yo

Average Age

Experienced Board: AVXL's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AVXL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.


Top Shareholders

Company Information

Anavex Life Sciences Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Anavex Life Sciences Corp.
  • Ticker: AVXL
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$904.732m
  • Shares outstanding: 69.49m
  • Website: https://www.anavex.com

Number of Employees


Location

  • Anavex Life Sciences Corp.
  • 51 West 52nd Street
  • 7th Floor
  • New York
  • New York
  • 10019
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVXLNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDApr 2006
12X1DB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2006
0HFRLSE (London Stock Exchange)YesCommon SharesGBUSDApr 2006

Biography

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/26 23:55
End of Day Share Price2021/02/26 00:00
Earnings2020/12/31
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.